Cash Flow Cyfuse Biomedical KK Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-761.00
-869.00
-586.00
-471.00
144.00
-327.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
87.00
-11.00
-22.00
-38.00
-7.00
-18.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-534.00
-760.00
-562.00
-403.00
161.00
-294.00
Cash Flow from Investing Activities
-397.00
-8.00
-19.00
-430.00
-50.00
0.00
Cash Flow from Financing Activities
1,256.00
-52.00
18.00
2,658.00
229.00
488.00
Net Cash Inflow / Outflow
323.00
-821.00
-563.00
1,824.00
340.00
194.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in JPY Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Cyfuse Biomedical KK
Figures in Million
consolidated Cash Flow Results
Change(JPY)
Change(%)
Profit Before Tax
-761.301
-813.125
52.00
6.37%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
87.426
-15.589
102.00
660.82%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-534.793
-815.021
281.00
34.38%
Cash Flow from Investing Activities
-397.564
-0.279
-397.00
-142396.06%
Cash Flow from Financing Activities
1256.323
1121.527
135.00
12.02%
Net Cash Inflow / Outflow
323.966
306.227
17.00
5.79%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is 29.68% vs -35.26% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
-534.79
-760.55
29.68%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
